Nav: Home

Probing the mystery of how cancer cells die

December 17, 2015

BUFFALO, N.Y. -- You've probably never heard of 'sphingolipids' before. But these curiously named organic compounds play a vital role in one of humanity's most well-known diseases: cancer.

Sphingolipids are a type of organic molecule found inside the body. Their odd appellation comes from the chemical 'sphingosine,' which forms one of the lipids' building blocks and has been said to be named after the riddle-telling sphinx. (The famed scientist Johann Ludwig Wilhelm Thudichum wrote in 1884 that he chose to call the compound sphingosine "in commemoration of the many enigmas which it presented to the inquirer.")

One mystery that remains today is the role that sphingolipids play in cancer -- in particular, the way in which cancer cells die.

A new study by University at Buffalo scientists sheds light on this topic, tracing how levels of various sphingolipids spike inside cancer cells when the cells are undergoing a highly organized form of cellular death called apoptosis.

In normal cells, apoptosis - akin to cellular suicide -- is carried out when a cell is damaged. The self-destruction is healthy: It's thought to help the body rid itself of dysfunctional cells.

Cancer cells are adept at evading apoptosis, which is one reason they multiply out of control. But in the new study, the scientists forced the cells to commit suicide, then carefully tracked what happened inside the cells as they self-destructed.

"A better understanding of the machinery of apoptosis, at the fundamental level, can perhaps help us find new therapeutics for cancer," said G. Ekin Atilla-Gokcumen, PhD, the study's senior author and an assistant professor of chemistry in the UB College of Arts and Sciences.

Previous studies have established that sphingolipid levels rise during apoptosis in cancer cells, but the new research -- which will be published on Dec. 17 in the journal Chemistry & Biology -- makes two important contributions.

First, the scientists found that the sphingolipid spikes may be unique to cancer. The team observed the phenomenon in three types of cancer cells (colon, ovarian and breast) during apoptosis, but not in two types of noncancerous cells (colon fibroblast cells, and retinal epithelial cells) undergoing the same process, Atilla-Gokcumen said.

Second, the scientists were able to create a detailed portrait of how the levels of many different sphingolipid compounds changed over time as death unfolded.

"We show that dying cancer cells appear to carefully tune the levels of individual sphingolipids as apoptosis progresses," Atilla-Gokcumen said. "Different compounds accumulate at different rates. Our results build on evidence that numerous sphingolipids are involved in managing this process of cellular death."

The study used a powerful technique called untargeted lipodomics to analyze the entire lipodome -- the collection of all lipids within cells. Lipids, which include compounds like fats and waxes, are one of the major classes of molecules found in the body, and there are thousands of them.

Despite this huge diversity, the study found that sphingolipids accounted for nearly 90 percent of lipids that accumulated in colon cancer cells during apoptosis.

The findings emphasize what previous studies have found: that sphingolipids, which have been linked to some of the body's most mysterious processes, such as cell proliferation and differentiation, appear to be highly active during cellular suicide.

The research also raises new questions, including what accounts for the differences in sphingolipid changes inside cancerous and noncancerous cells. The UB team found that noncancerous colon cells already had high levels of sphingolipids prior to apoptosis, whereas colon cancer cells had lower levels. This could help explain why sphingolipids spiked in the cancer cells during apoptosis but not in noncancerous cells, but more research must be done before scientists can understand the implications of this finding.
-end-


University at Buffalo

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#514 Arctic Energy (Rebroadcast)
This week we're looking at how alternative energy works in the arctic. We speak to Louie Azzolini and Linda Todd from the Arctic Energy Alliance, a non-profit helping communities reduce their energy usage and transition to more affordable and sustainable forms of energy. And the lessons they're learning along the way can help those of us further south.